Scientists first discovered that the A636T mutation in the GRIA1 gene, which encodes a key component of AMPA receptors, disrupts brain development. These receptors mediate signaling between neurons and are essential for learning and memory formation. The mutation disrupts the natural changes in the receptors during brain development. As a result, too much calcium enters neurons, leading to their damage and death.
Experiments showed that mice with this mutation gradually developed degeneration of hippocampal neurons, inflammation, memory and learning impairments, and changes in social behavior, according to the Johns Hopkins University website.
For treatment, scientists created an antisense oligonucleotide (ASO)—a short synthetic molecule that recognizes a specific RNA and suppresses its activity. The drug selectively targeted the mutant copy of the GRIA1 gene, leaving the normal copy intact. This reduced the production of the defective protein while maintaining production of its healthy counterpart.
A single administration of the drug shortly after birth prevented damage to hippocampal neurons, restored normal synaptic function, and reduced neuroinflammation. The animals also showed significant improvements in learning, memory, and social behavior.
"Suppressing a specific genetic mutation could prevent many developmental brain disorders," the authors said.
They currently plan to continue preclinical experiments on mouse models and human cells. If successful, the therapy could provide treatment for various neurological disorders, such as autism, intellectual disabilities, and others.
Previously, RNA therapy reversed amyotrophic lateral sclerosis in humans for the first time.
